Digital biomarkers are advancing Alzheimer's diagnosis. A review of 431 studies and 86 AI models shows promise in areas like motor activity and speech analysis, with an average AUC of 0.887 for AD models. However, external validation and model calibration remain underutilized.
#MedSky #MLSky

AI Intern Job Posting

Job Tittle: AI for Drug Discovery Intern
 
Job Details: 
📍 Location: Remote
⏳ Duration: 3-6 months 
🗓 Start Date: Flexible
💰 Compensation: Paid

The FDA's Digital Health Advisory Committee urges a total product life cycle approach for generative AI in medical devices, tackling regulatory challenges like output unpredictability and foundation model scope. 🩺🖥️

🧪 RhoFold+, a deep-learning tool, predicts RNA 3D structures in 0.14 seconds with high accuracy, tackling RNA flexibility and data scarcity. Applications: drug development, synthetic biology. 🧬🖥️

My colleague Prof. Vlad Pena here at the @icrlondon.bsky.social has a job opening for a post-doctoral research fellow. The primary interest of the Pena lab is the structural biology (#cryoEM) of spliceosomal complexes. Interested? Please have a look:
jobs.icr.ac.uk/vacancies/10...

We just released 8 new data wrangling tutorials for biologists! sandbox.bio/community/da... 💻 🧬

Sandbox.bio is a neat resource for learning data wrangling for bioinformatics! The tutorials are straightforward and I’ve definitely used it here and there to brush up on my CLI skills 🤩

Have tutorial ideas? Check out their GitHub to learn how to contribute to the project 👩🏽‍💻 💻 🧬

AI is reshaping drug discovery and clinical trials, prompting the FDA to weigh new patient safety rules. Firms like PhaseV and BioPhy use AI for precise patient matching and trial diversity, enhancing efficiency but narrowing commercial reach. 🩺🖥️ #MLSky 💊

This ability to bind to specific molecules makes aptamers very useful for a variety of applications, including biomarker discovery, drug development, and diagnostics.